Reported Earnings • May 05
First quarter 2026 earnings released: Rp0.05 loss per share (vs Rp0.56 profit in 1Q 2025) First quarter 2026 results: Rp0.05 loss per share (down from Rp0.56 profit in 1Q 2025). Revenue: Rp479.1b (up 8.7% from 1Q 2025). Net loss: Rp838.7m (down 109% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • Apr 27
PT Sarana Meditama Metropolitan Tbk, Annual General Meeting, Jun 09, 2026 PT Sarana Meditama Metropolitan Tbk, Annual General Meeting, Jun 09, 2026. Reported Earnings • Mar 31
Full year 2025 earnings released: EPS: Rp1.75 (vs Rp0.69 in FY 2024) Full year 2025 results: EPS: Rp1.75 (up from Rp0.69 in FY 2024). Revenue: Rp1.86t (up 9.1% from FY 2024). Net income: Rp30.1b (up 154% from FY 2024). Profit margin: 1.6% (up from 0.7% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 03
Third quarter 2025 earnings released: EPS: Rp1.09 (vs Rp0.093 in 3Q 2024) Third quarter 2025 results: EPS: Rp1.09 (up from Rp0.093 in 3Q 2024). Revenue: Rp492.3b (up 14% from 3Q 2024). Net income: Rp18.6b (up Rp17.0b from 3Q 2024). Profit margin: 3.8% (up from 0.4% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Board Change • Oct 24
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Independent Commissioner Heru Kristiyana was the last independent director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • May 06
PT Sarana Meditama Metropolitan Tbk, Annual General Meeting, Jun 18, 2025 PT Sarana Meditama Metropolitan Tbk, Annual General Meeting, Jun 18, 2025. Location: jakarta Indonesia Reported Earnings • Oct 31
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: Rp433.6b (up 6.0% from 3Q 2023). Net income: Rp1.60b (down 86% from 3Q 2023). Profit margin: 0.4% (down from 2.8% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 126 percentage points per year, which is a significant difference in performance. New Risk • Sep 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin). New Risk • Aug 03
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.5% Last year net profit margin: 1.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 03
Second quarter 2024 earnings released: Rp0.37 loss per share (vs Rp0.19 loss in 2Q 2023) Second quarter 2024 results: Rp0.37 loss per share (further deteriorated from Rp0.19 loss in 2Q 2023). Revenue: Rp411.9b (up 15% from 2Q 2023). Net loss: Rp6.45b (loss widened 100% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance. Reported Earnings • May 04
First quarter 2024 earnings released: EPS: Rp0.08 (vs Rp0.10 in 1Q 2023) First quarter 2024 results: EPS: Rp0.08 (down from Rp0.10 in 1Q 2023). Revenue: Rp435.8b (up 20% from 1Q 2023). Net income: Rp1.43b (down 18% from 1Q 2023). Profit margin: 0.3% (down from 0.5% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Reported Earnings • Mar 30
Full year 2023 earnings released: EPS: Rp0.71 (vs Rp0.25 in FY 2022) Full year 2023 results: EPS: Rp0.71 (up from Rp0.25 in FY 2022). Revenue: Rp1.54t (up 10% from FY 2022). Net income: Rp12.3b (up 182% from FY 2022). Profit margin: 0.8% (up from 0.3% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 03
Third quarter 2023 earnings released: EPS: Rp0.66 (vs Rp1.37 in 3Q 2022) Third quarter 2023 results: EPS: Rp0.66 (down from Rp1.37 in 3Q 2022). Revenue: Rp409.0b (up 7.7% from 3Q 2022). Net income: Rp11.5b (down 38% from 3Q 2022). Profit margin: 2.8% (down from 4.9% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 02
Second quarter 2023 earnings released: Rp0.20 loss per share (vs Rp2.28 loss in 2Q 2022) Second quarter 2023 results: Rp0.20 loss per share (improved from Rp2.28 loss in 2Q 2022). Revenue: Rp358.1b (up 24% from 2Q 2022). Net loss: Rp3.23b (loss narrowed 90% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 70% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
No independent directors There are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Director G.A. Kusmiati is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • May 04
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: EPS: Rp0.65 (down from Rp3.30 in 1Q 2021). Revenue: Rp349.5b (up 60% from 1Q 2021). Net income: Rp6.15b (down 84% from 1Q 2021). Profit margin: 1.8% (down from 18% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.2%. Earnings per share (EPS) missed analyst estimates by 37%. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Board Change • Apr 27
No independent directors There are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Director G.A. Kusmiati is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Apr 11
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: Rp10.23 (up from Rp76.18 loss in FY 2020). Revenue: Rp1.27t (up 151% from FY 2020). Net income: Rp138.6b (up Rp588.0b from FY 2020). Profit margin: 11% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 6.2%. Earnings per share (EPS) missed analyst estimates by 37%. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Jan 31
Investor sentiment improved over the past week After last week's 15% share price gain to Rp376, the stock trades at a trailing P/E ratio of 41.5x. Average trailing P/E is 18x in the Healthcare industry in Indonesia. Total returns to shareholders of 2.3% over the past three years. Reported Earnings • Jul 30
Second quarter 2021 earnings released: EPS Rp9.08 (vs Rp5.03 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: Rp219.2b (up 177% from 2Q 2020). Net income: Rp59.4b (up Rp89.1b from 2Q 2020). Profit margin: 27% (up from net loss in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Feb 24
New 90-day high: Rp420 The company is up 94% from its price of Rp216 on 26 November 2020. The Indonesian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 15% over the same period. Is New 90 Day High Low • Feb 06
New 90-day high: Rp418 The company is up 147% from its price of Rp169 on 06 November 2020. The Indonesian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 17% over the same period. Is New 90 Day High Low • Jan 07
New 90-day high: Rp358 The company is up 196% from its price of Rp121 on 09 October 2020. The Indonesian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 12% over the same period. Is New 90 Day High Low • Dec 05
New 90-day high: Rp226 The company is up 95% from its price of Rp116 on 04 September 2020. The Indonesian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 16% over the same period. Is New 90 Day High Low • Nov 17
New 90-day high: Rp179 The company is up 129% from its price of Rp78.00 on 19 August 2020. The Indonesian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 4.0% over the same period. Reported Earnings • Nov 16
Third quarter 2020 earnings released: Rp69.53 loss per share The company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: Rp127.5b (down 201% from 3Q 2019). Net loss: Rp410.2b (loss widened 319% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 124% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Oct 13
New 90-day high: Rp129 The company is up 95% from its price of Rp66.00 on 15 July 2020. The Indonesian market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 7.0% over the same period.